Compare TDOC & ODTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TDOC | ODTX |
|---|---|---|
| Founded | 2002 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 2015 | 2025 |
| Metric | TDOC | ODTX |
|---|---|---|
| Price | $5.78 | $19.10 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 23 | 7 |
| Target Price | $7.59 | ★ $37.00 |
| AVG Volume (30 Days) | ★ 3.1M | 290.9K |
| Earning Date | 10-28-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.58 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,406,840,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 18.41 | N/A |
| 52 Week Low | $4.40 | $15.10 |
| 52 Week High | $9.89 | $29.05 |
| Indicator | TDOC | ODTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.02 | 40.25 |
| Support Level | $5.08 | $15.10 |
| Resistance Level | $6.67 | $19.60 |
| Average True Range (ATR) | 0.21 | 1.73 |
| MACD | -0.00 | -0.39 |
| Stochastic Oscillator | 33.81 | 26.25 |
Teladoc Health Inc is engaged in the provision of virtual healthcare services, connecting patients, providers, and healthcare systems through technology-enabled platforms. The company has two reportable segments: Integrated Care and BetterHelp. The Integrated Care segment provides virtual healthcare solutions, including primary care, mental health, chronic care management, and telehealth enablement services for employers, insurers, and healthcare systems, mainly on a business-to-business basis, while the BetterHelp segment offers direct-to-consumer online mental health services, including counseling and therapy delivered through digital platforms. It generates the majority of its revenue from the Integrated Care segment.
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.